Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Símbolo de cotizaciónLTRN
Nombre de la empresaLantern Pharma Inc
Fecha de salida a bolsaJun 11, 2020
Director ejecutivoMr. Panna L. Sharma
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 11
Dirección1920 Mckinney Avenue
CiudadDALLAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal75201
Teléfono19722771136
Sitio Webhttps://www.lanternpharma.com/
Símbolo de cotizaciónLTRN
Fecha de salida a bolsaJun 11, 2020
Director ejecutivoMr. Panna L. Sharma
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos